Literature DB >> 26479275

Decernotinib: A Next-Generation Jakinib.

Massimo Gadina1, Daniella M Schwartz1, John J O'Shea1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26479275      PMCID： PMC5026186          DOI： 10.1002/art.39463

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  15 in total

Review 1.  Jaks and STATs: biological implications.

Authors:  W J Leonard; J J O'Shea
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

Review 2.  The JAK-STAT pathway: impact on human disease and therapeutic intervention.

Authors:  John J O'Shea; Daniella M Schwartz; Alejandro V Villarino; Massimo Gadina; Iain B McInnes; Arian Laurence
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

3.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.

Authors:  Gerd R Burmester; Ricardo Blanco; Christina Charles-Schoeman; Jürgen Wollenhaupt; Cristiano Zerbini; Birgitta Benda; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Koshika Soma; John Bradley; Charles Mebus
Journal:  Lancet       Date:  2013-01-05       Impact factor: 79.321

4.  VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.

Authors:  Sudipta Mahajan; James K Hogan; Dina Shlyakhter; Luke Oh; Francesco G Salituro; Luc Farmer; Thomas C Hoock
Journal:  J Pharmacol Exp Ther       Date:  2015-03-11       Impact factor: 4.030

5.  Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.

Authors:  Iain B McInnes; Ho-Youn Kim; Sang-Heon Lee; David Mandel; Yeong-Wook Song; Carol A Connell; Zhen Luo; M Julia Brosnan; Andrea Zuckerman; Samuel H Zwillich; John D Bradley
Journal:  Ann Rheum Dis       Date:  2013-03-12       Impact factor: 19.103

6.  Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.

Authors:  Luc J Farmer; Mark W Ledeboer; Thomas Hoock; Michael J Arnost; Randy S Bethiel; Youssef L Bennani; James J Black; Christopher L Brummel; Ananthsrinivas Chakilam; Warren A Dorsch; Bin Fan; John E Cochran; Summer Halas; Edmund M Harrington; James K Hogan; David Howe; Hui Huang; Dylan H Jacobs; Leena M Laitinen; Shengkai Liao; Sudipta Mahajan; Valerie Marone; Gabriel Martinez-Botella; Pamela McCarthy; David Messersmith; Mark Namchuk; Luke Oh; Marina S Penney; Albert C Pierce; Scott A Raybuck; Arthur Rugg; Francesco G Salituro; Kumkum Saxena; Dean Shannon; Dina Shlyakter; Lora Swenson; Shi-Kai Tian; Christopher Town; Jian Wang; Tiansheng Wang; M Woods Wannamaker; Raymond J Winquist; Harmon J Zuccola
Journal:  J Med Chem       Date:  2015-09-10       Impact factor: 7.446

7.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).

Authors:  P Macchi; A Villa; S Giliani; M G Sacco; A Frattini; F Porta; A G Ugazio; J A Johnston; F Candotti; J J O'Shea
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

8.  Tofacitinib versus methotrexate in rheumatoid arthritis.

Authors:  Eun Bong Lee; Roy Fleischmann; Stephen Hall; Bethanie Wilkinson; John D Bradley; David Gruben; Tamas Koncz; Sriram Krishnaswami; Gene V Wallenstein; Chuanbo Zang; Samuel H Zwillich; Ronald F van Vollenhoven
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

9.  Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.

Authors:  Christina Charles-Schoeman; Roy Fleischmann; Jean Davignon; Howard Schwartz; Scott M Turner; Carine Beysen; Mark Milad; Marc K Hellerstein; Zhen Luo; Irina V Kaplan; Richard Riese; Andrea Zuckerman; Iain B McInnes
Journal:  Arthritis Rheumatol       Date:  2015-03       Impact factor: 10.995

10.  Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation.

Authors:  Lauren A Zenewicz; George D Yancopoulos; David M Valenzuela; Andrew J Murphy; Margaret Karow; Richard A Flavell
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745
View more
  13 in total

1.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

Review 2.  The role of the JAK/STAT signal pathway in rheumatoid arthritis.

Authors:  Charles J Malemud
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-05-19       Impact factor: 5.346

Review 3.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

Review 4.  Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

Authors:  Massimo Gadina; Nathalia Gazaniga; Laura Vian; Yasuko Furumoto
Journal:  J Autoimmun       Date:  2017-07-01       Impact factor: 7.094

Review 5.  JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.

Authors:  George E Fragoulis; Iain B McInnes; Stefan Siebert
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 6.  Clinical efficacy of new JAK inhibitors under development. Just more of the same?

Authors:  Rene Westhovens
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

7.  Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis.

Authors:  Divya Jain; Trishang Udhwani; Shreshtha Sharma; Aishwarya Gandhe; Palugulla Bhaskar Reddy; Anuraj Nayarisseri; Sanjeev Kumar Singh
Journal:  Bioinformation       Date:  2019-02-28

Review 8.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

Review 9.  Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors.

Authors:  Alba Garrido-Trigo; Azucena Salas
Journal:  J Crohns Colitis       Date:  2020-08-01       Impact factor: 9.071

Review 10.  Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.

Authors:  Anniina T Virtanen; Teemu Haikarainen; Juuli Raivola; Olli Silvennoinen
Journal:  BioDrugs       Date:  2019-02       Impact factor: 5.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.